



BI 456906- Once a week Injection

An investigation drug an GLP-1/glucagon agonist

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

High unmet medical need among the up to 444 million adults estimated to be living with NASH

The GLP-1/glucagon compound derived from the natural gut hormone oxyntomodulin activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments. It is also being investigated as a potential treatment option for adults living with diabetes and for adults living with obesity.

NCT ID	Indication	Phase	Status	Sample Size	Countries
NCT04153929	Type 2 Diabetes	2	Recruiting	410	US, Canada, Australia, New Zealand, EU, Japan, UK, Taiwan
NCT04771273	Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)	2	Recruiting	240	Korea, New Zealand
NCT04667377	Overweight or Obesity to Lose Weight	2	Recruiting	350	US, Australia, Canada, New Zealand, EU
NCT03175211	Safety, Tolerability, Pharmacokinetics & Pharmacodynamics	1	Completed	20	Germany
NCT03591718	Dose Estimation in Patients with Obesity	1	Completed	131	Germany
NCT04384081	Safety, Tolerability, Pharmacokinetics & Pharmacodynamics	1	Completed	37	Japan

6 Doses are under investigation across 87 locations